Čeština
|
Dansk
|
Deutsch
|
English
|
Español
|
Français
|
Italiano
|
Nederlands
|
Norsk
|
Polski
|
Português
|
Pусский
|
Suomi
|
Svenska
|
US
EHDN2016
DISEASE
NETWORK
REGISTRY
PROJECTS
LOGIN
EHDN2012 - Documents - Presentations
-
Uutiset
Projekti
Rahoittaja
Johtokunta
Writing Committee Strategic ...
Neuvoa antava lautakunta
Keskuskoordinaatio
Kielikoordinaatio
Fellowship Programme
Perustuslaki 2008
Äänestys
Jäsenet
Jäsenyyden hakeminen
Tutkimuspaikat
Työryhmät
Tapahtumat
EHDN 2016
EHDN 2014
EHDN 2012
Introduction
Announcement
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Important Dates
Registration
Travel & Accommodation
EHA Registration
EHA Programme
Reception Dinner
About Stockholm
Abstract Submission
Reimbursement
Documents
Handouts
Presentations
Posters
Contacts
Feedback & Evaluation
EHDN 2010
EHDN 2008
EHDN 2007
EHDN 2006
EHDN 2005
EHDN 2004
Yhteydenpito
Työtarjoukset
päivämäärä
kuvaus
koko
kirjoittaja
asiakirja
04.05.26
Stem cells for basic research on HD
32 kB
anonymous
ehdn-2012-ellerby
04.05.26
Stem cells for basic research on HD
32 kB
anonymous
ehdn-2012-l-thompson-empty-file
04.05.26
Keynote presentations
32 kB
anonymous
ehdn-2012-aronin-empty-file
04.05.26
Post-translational modifications of huntingtin
32 kB
anonymous
ehdn-2012-saudou-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-quarrell-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-craufurd-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-reilmann-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-j-thompson-empty-file
04.05.26
Updates on lowering huntingtin (htt) levels
32 kB
anonymous
ehdn-2012-davidson-empty-file
04.05.26
HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models
32 kB
anonymous
ehdn-2012-bates-empty-file
04.05.26
Sirt1-inhibition: SienaBiotech
32 kB
anonymous
ehdn-2012-caricasole-empty-file
04.05.26
PDE-10-inhibition: Pfizer
32 kB
anonymous
ehdn-2012-schmidt-empty-file
04.05.26
PDE-4-inhibition: GSK
32 kB
anonymous
ehdn-2012-gray-empty-file
04.05.26
Htt lowering: Medtronic-Alnylam/Isis/CHDI
32 kB
anonymous
ehdn-2012-mcdonald-empty-file
04.05.26
Phenotyping neural networks in an ovine model of HD
32 kB
anonymous
ehdn-2012-perentos-empty-file
04.05.26
Aging pathway and poly-Q neurotoxicity
32 kB
anonymous
ehdn-2012-nollen
04.05.26
NeuroNet and its potential for the study of neurodegeneration
32 kB
anonymous
ehdn-2012-wanker-empty-file
04.05.26
Behavioral assessment and management of behavioral issues
32 kB
anonymous
ehdn-2012-anderson-empty-file
04.05.26
Differential diagnosis of chorea
32 kB
anonymous
ehdn-2012-walker-empty-file
04.05.26
Post-translational modifications and proteolysis of huntingtin
32 kB
anonymous
ehdn-2012-truant-empty-file
04.05.26
Advanced HD Working Group
32 kB
anonymous
ehdn-2012-youssov-empty-file
04.05.26
Animal studies on the effects of physiotherapy
32 kB
anonymous
ehdn-2012-brooks-empty-file
04.05.26
RNA toxicity in poly-Q disorders
32 kB
anonymous
ehdn-2012-krzyzosiak
04.05.26
Longevity pathways and their relevance to human disease
32 kB
anonymous
ehdn-2012--aguilaniu-empty-file
04.05.26
Frequency of Huntington Disease - Greater than you think
32 kB
anonymous
ehdn-2012-hayden-empty-file
04.05.26
What are we really looking for in an HD drug?
32 kB
anonymous
ehdn-2012-sampaio-empty-file
04.05.26
Care, coping and research in HD – the earlier the better!
32 kB
anonymous
ehdn-2012-duerr-empty-file
04.05.26
Human physiotherapy studies
32 kB
anonymous
ehdn-2012-busse-empty-file
04.05.26
Default-mode network changes in preclinical Huntington´s disease
32 kB
anonymous
ehdn-2012-orth-empty-file
04.05.26
Cognitive alterations in HD
32 kB
anonymous
ehdn-2012-stout-empty-file
04.05.26
Lessons of the day
32 kB
anonymous
ehdn-2012-wild-empty-file
04.05.26
Clinical management of Huntington’s disease
32 kB
anonymous
ehdn-2012-nance-empty-file
04.05.26
Update on stem cell research: clinical potentials
32 kB
anonymous
ehdn-2012-brundin-empty-file
04.05.26
Critical consideration of the criteria for the motor diagnosis of HD
32 kB
anonymous
ehdn-2012-paulsen-empty-file
04.05.26
Longitudinal functional and connectivity changes during working memory performance in HD
32 kB
anonymous
ehdn-2012-georgiou-karistianis-empty-f...
04.05.26
Better global and cognitive functioning for choreatic compared to hypokinetic- rigid HD
32 kB
anonymous
ehdn-2012-t-hart-empty-file
04.05.26
Bupropion: ACTION-HD
32 kB
anonymous
ehdn-2012-priller-empty-file
04.05.26
Overview of CHDI drug development programs
32 kB
anonymous
ehdn-2012-pacifici
04.05.26
Drug discovery and development process
32 kB
anonymous
ehdn-2012-kwak-empty-file
04.05.26
Lessons of the day
32 kB
anonymous
ehdn-2012-wild-empty-file
04.05.26
Standards of Care
32 kB
anonymous
ehdn-2012-rea-empty-file
04.05.26
EHDN Update - EC elections, SBAC elections, Structure of EHDN
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
04.05.26
Dopaminergic stabilization in HD: pridopidine
32 kB
anonymous
ehdn-2012-kieburtz-empty-file
04.05.26
Reach2HD PBT2
32 kB
anonymous
ehdn-2012-stout-empty-file
04.05.26
PREQUEL EHDN
32 kB
anonymous
ehdn-2012-ross-empty-file
04.05.26
Juvenile Huntington's disease
32 kB
anonymous
a03-juvenile-hd
04.05.26
Default-mode network changes in preclinical Huntington’s disease
32 kB
anonymous
a04-default-mode-network-changes
04.05.26
New assessment tools (cognitive batteries)
32 kB
anonymous
ehdn-2012-stout-empty-file
04.05.26
Poster Awards
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
04.05.26
REGISTRY and Enroll-HD
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
04.05.26
Better global and cognitive functioning for choreatic compared to hypokinetic-rigid Huntington’s disease
32 kB
anonymous
a06-better-global-and-cognitive-functi...
04.05.26
Progress in HD research and HD advocacy: a personal view
32 kB
anonymous
ehdn-2012-sabine-empty-file
04.05.26
Juvenile HD Working Group
32 kB
anonymous
ehdn-2012-quarrell
04.05.26
MRI as a potential marker for HD
32 kB
anonymous
ehdn-2012-scahill
04.05.26
Defining predictors of disease
32 kB
anonymous
a11-induced-pluripotent-stem-cells
04.05.26
Presentation of the HDYO website
32 kB
anonymous
ehdn-2012-ellison
04.05.26
Huntingtin
32 kB
anonymous
ehdn-2012-cattaneo
04.05.26
Falling in love, staying in love
32 kB
anonymous
eha-2012-mol
04.05.26
Defining predictors of disease
32 kB
anonymous
ehdn-2012-tabrizi
04.05.26
Critical consideration of the criteria for the motor diagnosis of Huntington disease
32 kB
anonymous
a07-critical-consideration-criteria-mo...
04.05.26
New assessment tools (cognitive batteries)
32 kB
anonymous
ehdn-2012-bachoud-levi-empty-file
04.05.26
Brain imaging as a potential marker for HD (PET)
32 kB
anonymous
ehdn-2012-varrone-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-reilmann-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-craufurd-empty-file
04.05.26
Scientific strategy of EHDN
32 kB
anonymous
ehdn-2012-bronzova
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-quarrell-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-thompson-empty-file
04.05.26
Common issues/problems/inconsistencies in HD assessments
32 kB
anonymous
ehdn-2012-ferreira-empty-file
04.05.26
HD for Basic Scientists
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
11.04.13
Plenary Session I: ‘A look ahead’
33
blankin
Plenary-Session-I
11.04.13
Plenary Session II: ‘Frontiers in biology and their relevance to Huntington’s disease’
33
blankin
Plenary-Session-II
11.04.13
Plenary Session III: ‘Science practice at EHDN’
33
blankin
Plenary-Session-III
11.04.13
Short Communications I: 'Scientific Presentations: 10’ and 5’ questions – selected from submissions'
33
blankin
Short-Communications-I
11.04.13
Plenary Session IV: Keynote presentations
33
blankin
Plenary-Session-IV
11.04.13
Roundup I
33
blankin
Roundup-I
11.04.13
Breakfast teaching courses Sat
33
blankin
Breakfast-teaching-courses-sat
11.04.13
Plenary Session V: ‘Understanding and manipulating the pathogenic process in Huntington’s disease’
33
blankin
Plenary-Session-V
11.04.13
Plenary Session VI: Keynote presentations
33
blankin
Plenary-Session-VI
11.04.13
Short communications II: Scientific presentations
33
blankin
Short-communications-II
11.04.13
Plenary Session VII: ‘Therapeutic development programs in Huntington’s Disease’
33
blankin
Plenary-Session-VII
08.04.13
Plenary Session VIII: EHDN Business Meeting
33
blankin
Plenary-Session-VIII
08.04.13
Roundup II
33
blankin
Roundup-II
08.04.13
Breakfast teaching courses Sun
33
blankin
Breakfast-teaching-courses-sun
08.04.13
Plenary Session IX: ‘Tools and outcome to monitor disease progression and response to therapy’
33
blankin
Plenary-Session-IX
08.04.13
Roundup III
33
blankin
Roundup-III
08.04.13
EHA meeting
33
blankin
EHA-meeting
08.04.13
Oral Presentations
33
blankin
Oral-Presentations
Kansio sisältää 87 asiakirjaa.
about us
|
privacy statement
|
disclaimer
|
terms of use